SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

SciClone Pharmaceuticals (Holdings) Limited

6600

KYG4271B1023

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
18.5 ^HKD	+0.43%		+0.54%	+32.90%

May. 16	Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
Apr. 18	Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31	MT

Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong

May 16, 2024 at 04:31 am EDT

The board of directors (the ?Board?) of SciClone Pharmaceuticals (Holdings) Limited (the ?Company?) announced that with effect from May 16, 2024, the address of the principal place of business in Hong Kong of the Company has changed from 3401A, Windsor House, 311 Gloucester Road, Causeway Bay, Hong Kong to 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong.

Latest news about SciClone Pharmaceuticals (Holdings) Limited

Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong	May. 16	CI
Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31	Apr. 18	MT
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit	Apr. 01	MT
Sciclone Pharmaceuticals Limited Announces Executive Changes	Mar. 28	CI
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
GL China Opportunities Fund IV L.P. and GL China Opportunities Fund IV L.P., managed by GL Capital Group and GL Capital Management GP L.P. agreed to acquire 66.69% stake in SciClone Pharmaceuticals Limited for HKD 7.9 billion.	Mar. 27	CI
SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3%	Jan. 31	MT
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China	Jan. 31	CI
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer	Nov. 07	CI
SciClone Signs Licensing Deal with Menarini for Breast Cancer Drug; Shares Rise 3%	Nov. 07	MT
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China	Nov. 06	CI
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1	23-08-18	MT
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
SciClone Pharmaceuticals Doses First Patient in Phase 3 Study for Urinary Tract Infection Injection	23-07-04	MT
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China	23-07-04	CI
SciClone Commercially Launches Neuroblastoma Treatment in China	23-07-03	MT
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China	23-07-02	CI
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.	23-06-06	CI
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022	23-05-25	CI
Sciclone Pharmaceuticals Limited Elects Ms. Pan Rongrong as an Executive Director of the Company	23-05-25	CI
SciClone Pharmaceuticals Limited's Equity Buyback announced on May 20, 2022, has expired.	23-05-24	CI
Sciclone Pharmaceuticals Limited Announces Retirement of SHI Cen as Non-Executive Director	23-05-22	CI
Sciclone Pharmaceuticals Limited Declares Final Dividend for the Year Ended December 31, 2022, Payable on 28 June 2023	23-03-30	CI
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
China Approves SciClone's Investigational New Drug Status for Urinary Tract Infection Medication	23-03-20	MT

Chart SciClone Pharmaceuticals (Holdings) Limited

Duration

Period

Chart SciClone Pharmaceuticals (Holdings) Limited

More charts

Company Profile

SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.

Sector

Pharmaceuticals

Calendar

2024-08-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for SciClone Pharmaceuticals (Holdings) Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.13 CNY

Average target price

16.5 CNY

Spread / Average Target

-3.71%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED	+32.90%	1.43B
CSL LIMITED	-2.29%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
BIOGEN INC.	-13.07%	32.75B
UCB	+63.05%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B

Biopharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Pharmaceuticals

Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong

Latest news about SciClone Pharmaceuticals (Holdings) Limited

Chart SciClone Pharmaceuticals (Holdings) Limited

Company Profile

Income Statement Evolution

Ratings for SciClone Pharmaceuticals (Holdings) Limited

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals